Asako Murayama
Overview
Explore the profile of Asako Murayama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
817
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Honda T, Ishigami M, Ishizu Y, Imai N, Ito T, Yamamoto K, et al.
Hepatol Int
. 2025 Jan;
PMID: 39869245
Background And Aims: Hepatitis B virus (HBV) is prevalent worldwide and is difficult to eradicate. Current treatment strategies for chronic hepatitis B ultimately seek to achieve functional cure (FC); however,...
2.
Murayama A, Igarashi H, Yamada N, Aly H, Toyama M, Isogawa M, et al.
mSphere
. 2024 Sep;
9(10):e0051824.
PMID: 39345122
Importance: Hepatitis B virus (HBV) is the principal causative agent of chronic hepatitis. Despite the availability of vaccines in many countries, HBV infection has spread worldwide and caused chronic infection....
3.
Murayama A, Igarashi H, Yamada N, Aly H, Molchanova N, Lin J, et al.
Antiviral Res
. 2024 Jan;
223:105821.
PMID: 38272318
Although antimicrobial peptides have been shown to inactivate viruses through disruption of their viral envelopes, clinical use of such peptides has been hampered by a number of factors, especially their...
4.
Murayama A, Akari H, Kato T
Bio Protoc
. 2023 Jul;
13(14):e4779.
PMID: 37497458
An efficient cell culture system for hepatitis B virus (HBV) is indispensable for research on viral characteristics and antiviral agents. Currently, for HBV infection assays in cell culture, HBV genome-integrated...
5.
Momose H, Murayama A, Yamada N, Matsubayashi K, Matsuoka S, Ikebe E, et al.
Virol J
. 2023 May;
20(1):93.
PMID: 37165426
Background: Hepatitis B virus (HBV) infection is a global public health concern. Precise and sensitive detection of viral markers, including HBV DNA and HBs antigen (Ag), is essential to determine...
6.
Washizaki A, Murayama A, Murata M, Kiyohara T, Yato K, Yamada N, et al.
Nat Commun
. 2022 Sep;
13(1):5207.
PMID: 36064848
Although the current hepatitis B (HB) vaccine comprising small-HBs antigen (Ag) is potent and safe, attenuated prophylaxis against hepatitis B virus (HBV) with vaccine-escape mutations (VEMs) has been reported. We...
7.
Li X, Ito M, Aoyagi H, Murayama A, Aizaki H, Fukasawa M, et al.
Int J Mol Sci
. 2022 Aug;
23(15).
PMID: 35955844
In microbiological research, it is important to understand the time course of each step in a pathogen's lifecycle and changes in the host cell environment induced by infection. This study...
8.
Gad S, Sugiyama M, Tsuge M, Wakae K, Fukano K, Oshima M, et al.
PLoS Pathog
. 2022 Mar;
18(3):e1009983.
PMID: 35312737
Intracellular transport via microtubule-based dynein and kinesin family motors plays a key role in viral reproduction and transmission. We show here that Kinesin Family Member 4 (KIF4) plays an important...
9.
Murayama A, Momose H, Yamada N, Matsubayashi K, Muramatsu M, Hamaguchi I, et al.
Front Cell Infect Microbiol
. 2022 Feb;
11:793472.
PMID: 35186779
Aim: A reliable kit with high sensitivity and specificity is indispensable for diagnosing hepatitis C virus (HCV) infection. Detection kits for anti-HCV antibodies (anti-HCV) are used for screening, and quantification...
10.
Murayama A, Kato T
Vitam Horm
. 2021 Aug;
117:227-238.
PMID: 34420582
Until the development of direct-acting antivirals (DAAs), interferon (IFN)-based therapy had been the primary treatment strategy for patients with chronic hepatitis C, even though this therapy has a therapeutic limitations...